Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, is pleased to provide a corporate update.

“2019 was an important year for Biogenum,” said Dr Choi Jun-seok, Chairman and CEO of Biogenum. “The regulators accepted for review our studies and papers for Tau NonTangles™ - small molecule for Alzheimer’s disease treatment. We also made significant progress in building our commercial infrastructure in preparation for potential launch, including the hiring of our commercial senior leadership team. In addition, we continued to advance our clinical and preclinical development programs including Tau NonTangles™ - small molecule for Alzheimer’s disease treatment, for bipolar depression, and look forward to providing additional updates on these programs in the year ahead.”

Corporate Update
Tau NonTangles™ - small molecule for Alzheimer’s disease treatment Programs:
• Our new drug application for Tau NonTangles an investigational agent for the treatment of Alzheimer, is under review by the medical regulators.
• We continue to expand our infrastructure to support the commercialization of Tau NonTangles™ - small molecule for Alzheimer’s disease treatment, pending the medical regulator’s approval. In the fourth quarter of 2019, we appointed Hahn Se-young as Executive Vice President and Chief Commercial Officer. Hahn has extensive marketing and sales experience in various therapeutic areas, including neuroscience and cardiology. In addition, we have continued to expand our commercial leadership team and have now hired senior leaders across all the key commercial functions.
• As our clinical programs have advanced, we have supplemented our clinical development expertise with additional senior team members. We appointed Yoon Hae-joo as Executive Vice President and Chief Medical Officer. He has extensive experience in bringing neuropsychiatric products through late stage clinical development and regulatory approval.
• Favorable safety data from our Tau NonTangles™ - small molecule for Alzheimer’s disease treatment open-label safety switching study in patients with stable symptoms of Alzheimer were replicated and extended from short-term to long-term exposure. This second part of the study enrolled 400 patients for up to one year of treatment with Tau NonTangles™ after a switch from standard-of-care (SOC) antipsychotic therapy.

About Biogenum
Biogenum is a privately held biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, ALS and others. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Composed of proprietary chemistry and software, Biogenum delivers powerful answers using broadly installed instrument platforms. The company’s leadership team has decades of experience in drug discovery, translational strategy, corporate development and commercialization. Collectively, we have been instrumental in researching more than 10 drugs to be delivered in the market.

http://www.biogenum.com